1 Osman H, Shrestha S, Temin S, Ali ZV, Corvera RA, Ddungu HD, et al. Palliative Care in the Global Setting: ASCO Resource-Stratified Practice Guideline. JGO. 2018;(4):1–24.
2 Von Wartburg L. soins-palliatifs generaux recommandations et instruments de mise en oeuvre. 2015.
3 Hui et al. Concepts and Definitions for «Actively Dying». 2014.
4 White N. How accurate is the ‘Surprise Question’ at identifying patients at the end of life? A systematic review and meta-analysis. 2017;14.
5 Hamano J, Morita T, Inoue S, Ikenaga M, Matsumoto Y, Sekine R, et al. Surprise Questions for Survival Prediction in Patients With Advanced Cancer: A Multicenter Prospective Cohort Study. 2015;7.
6 Thompson AJ, Silveira MJ, Vitale CA, Malani PN. Antimicrobial Use at the End of Life Among Hospitalized Patients With Advanced Cancer. Am J Hosp Palliat Care. 2012;29(8):599–603.
7 Macedo F, Nunes C, Ladeira K, Pinho F, Saraiva N, Bonito N, et al. Antimicrobial therapy in palliative care: an overview. Support Care Cancer. 2018;26(5):1361–7.
8 Tagashira Y, Kawahara K, Takamatsu A, Honda H. Antimicrobial prescribing in patients with advanced-stage illness in the antimicrobial stewardship era. Infect Control Hosp Epidemiol. 2018;39(9):1023–9.
9 Taverner J, Ross L, Bartlett C, Luthe M, Ong J, Irving L, et al. Antimicrobial prescription in patients dying from chronic obstructive pulmonary disease: Antimicrobials in deaths from COPD. Intern Med J. 2019;49(1):66–73.
10 Morioka S, Mori M, Suzuki T, Yokomichi M, Hamano J, Morita T. Determinants of Physicians’ Attitudes Toward the Management of Infectious Diseases in Terminally Ill Patients With Cancer. Journal of Pain and Symptom Management. 2020;60(6):1109-1116.e2.
11 Vaughan L, Duckett AA, Adler M, Cain J. Ethical and Clinical Considerations in Treating Infections at the End of Life: Journal of Hospice & Palliative Nursing. 2019;21(2):110–5.
12 Mirhosseini M, Oneschuk D, Hunter B, Hanson J, Quan H, Amigo P. The Role of Antibiotics in the Management of Infection-Related Symptoms in Advanced Cancer Patients. J Palliat Care. 2006;22(2):69–74.
13 Marra AR, Puig-Asensio M, Balkenende E, Livorsi DJ, Goto M, Perencevich EN. Antibiotic use during end-of-life care: A systematic literature review and meta-analysis. Infect Control Hosp Epidemiol. 2021;42(5):523–9.
14 Helde-Frankling M, Bergqvist J, Bergman P, Björkhem-Bergman L. Antibiotic Treatment in End-of-Life Cancer Patients–A Retrospective Observational Study at a Palliative Care Center in Sweden. Cancers. 2016;8(9):84.
15 Rosenberg JH, Albrecht JS, Fromme EK, Noble BN, McGregor JC, Comer AC, et al. Antimicrobial Use for Symptom Management in Patients Receiving Hospice and Palliative Care: A Systematic Review. Journal of Palliative Medicine. 2013;16(12):1568–74.
16 Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse Events With Antibiotic Use in Hospitalized Patients. JAMA Intern Med. 2017;177(9):1308.
17 Leffler DA, Lamont JT. Clostridium difficile Infection. Longo DL, éditeur. N Engl J Med. 2015;372(16):1539–48.
18 Datta R, Juthani-Mehta M. Burden and Management of Multidrug-Resistant Organisms in Palliative Care. Palliat-Care. 2017;10:117822421774923.
19 Heckel M, Geißdörfer W, Herbst FA, Stiel S, Ostgathe C, Bogdan C. Nasal carriage of methicillin-resistant Staphylococcus aureus (MRSA) at a palliative care unit: A prospective single service analysis. Rohde H, éditeur. PLoS ONE. 2017;12(12):e0188940.
20 Givens JL, Jones RN, Shaffer ML, Kiely DK, Mitchell SL. Survival and Comfort After Treatment of Pneumonia in Advanced Dementia. Arch Intern Med [Internet]. 12 juill 2010 [cité 13 nov 2020];170(13). Disponible sur: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/archinternmed.2010.181
21 van der Maaden T, van der Steen JT, de Vet HCW, Hertogh CMPM, Koopmans RTCM. Prospective Observations of Discomfort, Pain, and Dyspnea in Nursing Home Residents With Dementia and Pneumonia. Journal of the American Medical Directors Association. 2016;17(2):128–35.
22 Reinbolt RE, Shenk AM, White PH, Navari RM. Symptomatic Treatment of Infections in Patients with Advanced Cancer Receiving Hospice Care. Journal of Pain and Symptom Management. 2005;30(2):175–82.
23 White PH, Kuhlenschmidt HL, Vancura BG, Navari RM. Antimicrobial Use in Patients with Advanced Cancer Receiving Hospice Care. Journal of Pain and Symptom Management. 2003;25(5):438–43.
24 Vitetta L, Kenner D, Sali A. Bacterial Infections in Terminally Ill Hospice Patients. Journal of Pain and Symptom Management. 2000;20(5):326–34.
25 Lopez S, Vyas P, Malhotra P, Finuf K, Magalee C, Nouryan C, et al. A Retrospective Study Analyzing the Lack of Symptom Benefit With Antimicrobials at the End of Life. Am J Hosp Palliat Care. 2020;104990912095174.
26 Blinderman CD, Billings JA. Comfort Care for Patients Dying in the Hospital. Longo DL, éditeur. N Engl J Med. 2015;373(26):2549–61.
27 Tilley C, Lipson J, Ramos M. Palliative Wound Care for Malignant Fungating Wounds. Nursing Clinics of North America. 2016;51(3):513–31.
28 Watanabe K, Shimo A, Tsugawa K, Tokuda Y, Yamauchi H, Miyai E, et al. Safe and effective deodorization of malodorous fungating tumors using topical metronidazole 0,75 % gel (GK567): a multicenter, open-label, phase III study (RDT.07.SRE.27013). Support Care Cancer. 2016;24(6):2583–90.
29 Ramasubbu DA, Smith V, Hayden F, Cronin P. Systemic antibiotics for treating malignant wounds. Cochrane Wounds Group, éditeur. Cochrane Database of Systematic Reviews [Internet]. 24 août 2017 [cité 25 févr 2021]; Disponible sur: http://doi.wiley.com/10.1002/14651858.CD011609.pub2
30 Zürcher S, Trellu LT. Erysipèle et dermohypodermite récidivants: prise en charge [Recurrent erysipelas and cellulitis: management]. Rev Med Suisse. 2015;11(468):759–62.
31 Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–10.